Absci, a data-first generative AI drug creation company, is partnering with AMD, a semiconductor company, to deploy AMD Instinct accelerators and ROCm software to power vital AI drug discovery workloads, as well as Absci’s…
Continue Reading
What You Should Know:
– TetraScience, a provider of scientific data cloud solutions announced a strategic collaboration with Microsoft to accelerate the adoption of artificial intelligence (AI) in the biopharmaceutical industry.
– The strategic partnership combines…
Continue Reading
Noam Solomon, CEO at Immunai
For over a decade, we’ve heard about AI’s transformative potential in therapeutics (Tx), but where’s the evidence? Has it all been hype? Can AI still revolutionize Tx? Or is there…
Continue Reading
Top News
Several health systems launch the Truveta Genome Project, which will create a database of genotypic and phenotypic information. The data will be collected by using leftover biospecimens from the routine lab tests of…
Continue Reading
Drug discovery startup Insilico Medicine and Italian pharmaceutical company Menarini Group announced their second licensing agreement, targeting unmet needs in oncology with a novel AI-discovered preclinical asset. The agreement grants Stemline Therapeutics, a subsidiary of…
Continue Reading
Acquisition Preparation: Startups must understand potential acquirers’ strategic goals and align their operations (e.g., revenue, margins, customer retention) to fit those goals.Relationships with key suppliers or partners can serve as a natural entry point…
Continue Reading
What You Should Know:
– Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced its upcoming acquisition by Renovaro, Inc. (NASDAQ: RENB) in a strategic move aimed at accelerating innovation and improving…
Continue Reading
What You Should Know:
– BrightInsight, Inc., a provider of regulated digital health solutions, has announced an expanded multi-year partnership with Sanofi, a global biopharmaceutical company. This expanded partnership builds on a successful collaboration that…
Continue Reading
Converge Bio has raised $5.5 million in seed funding led by TLV Partners.WHAT IT DOES
Converge Bio is a generative AI hub for Biotech and Pharma that allows the accelerated discovery and development of drugs…
What You Should Know:
– Converge Bio, a generative AI platform for accelerated drug discovery and development, today announced it has raised $5.5 million in seed funding, led by TLV Partners.
– Converge Bio’s platform uses large language…
Continue Reading
